Abstract. Human immediate early response 2 (IER2) has been reported to function as a potential transcriptional factor or transcriptional co-activator and seems to play a pivotal role in tumor cell motility and metastasis, however, its role and underlying mechanisms in hepatocellular carcinoma (HCC) remain unknown. Herein, we demonstrated that overexpression of IER2 in HCC cells increased cell adhesion to fibronectin, migration and invasion, whereas knockdown of IER2 displayed the opposite effects. In agreement with this phenotype, IER2 expression was positively correlated with the metastatic potential and integrin β1 (ITGB1) expression in HCC cell lines. Moreover, we demonstrated a critical role for IER2 in regulation of HCC cell-extracellular matrix (ECM) adhesion and motility by the transcriptionally promoted ITGB1. Furthermore, we showed that ITGB1-focal adhesion kinase (FAK)-Src-paxillin signal pathway activated by IER2 may contribute to the HCC cell-ECM adhesion and motility. These results demonstrated that IER2 promoted HCC cell adhesion and motility probably by directly increasing ITGB1 expression and subsequently activating the ITGB1-FAK-Src-paxillin signal pathway.
Introduction
Immediate early response 2 (IER2) or ETR101, a human homolog of mouse and rat for pip92 is a cellular immediate early response protein that is induced by extracellular stimuli, such as growth factors, 12-O-tetradecanoylphorbol-13-acetate, and some infection of pathogens (1) (2) (3) (4) . Previous studies have demonstrated that IER2 may function as a fibroblast growth factor intracellular binding protein 1-interacting protein, or as a DNA-binding protein acting as a transcriptional activator for myo-inositol 1-phosphate synthase gene (3, 5) . Recently, evidence suggests that IER2 seems to play a pivotal role in tumor cell motility and metastasis (6) , however, little is known about the mechanism involved. We have previously shown that IER2 regulated human umbilical vein endothelium cell motility, adhesion, in vitro capillary tube formation, and the actin cytoskeleton rearrangement in a FAK-dependent manner (7) . Furthermore, we also found that IER2, as a direct and functional target for miR-30c in the hepatocellular carcinoma (HCC) cell lines (SMMC-7721 and HepG2 cells), may function as a positive regulator in cell migration and invasion (8) , suggesting that IER2 may play a role in the HCC cell motility.
HCC is the fifth most commonly diagnosed human cancer worldwide, and the leading cause of death for the vast majority of HCC patients is a result of the direct metastases (9) , which is a complex process including cancer cells shed from the primary organization, cell-extracellular matrix (ECM) adhesion, cell migration and invading ECM, and each step of metastases is associated with changes in gene expression involved in cell migration, invasion and adhesion (10, 11) . Thus, understanding the underlying mechanisms involved in these processes will likely contribute to our insight to developing strategies for maximizing the efficacy of HCC treatment. Previous studies have shown that IER2 is upregulated in some metastatic cancer cells and in several human primary tumors, such as pancreas cancer, breast cancer and HCC (6) , and IER2 expression promotes tumor cell migration and invasion and correlates with the colorectal adenocarcinoma metastasis (6, 8) . However, the biological roles and underlying mechanisms involved in HCC of IER2 are largely unknown.
In the present study, we aimed to investigate the effect of IER2 on HCC cell motility and cell-ECM adhesion and spreading, and to unveil the underlying mechanisms by which IER2 regulated HCC cell motility and adhesion. We demonstrated that overexpression of IER2 in HCC cells promoted cell adhesion to fibronectin and motility, whereas knockdown expression of IER2 displayed the opposite effects. Furthermore, we demonstrated a critical role for IER2 in regulation of HCC cell-ECM adhesion and motility probably by the transcriptionally promoted integrin β1 (ITGB1) and then activated ITGB1-focal adhesion kinase (FAK)-Src-paxillin signal pathway.
Materials and methods
Cell lines and culture conditions. Human embryonic kidney (HEK) 293T cells, HCC cell lines HepG2 and SMMC-7721 were obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China), and MHCC97H and HCCLM3 cells were obtained from the KeyGen Biotech (Nanjing, China). All cells were routinely maintained in DMEM (Gibco-BRL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin, and cultured at 37˚C in a humidified atmosphere of 5% CO 2 .
Plasmid construction and lentiviral production. The full-length of human IER2 cDNA was amplified from pEZ-Lv105-IER2 vector obtained from GeneCopoeia (Rockville, MD, USA) by polymerase chain reaction (PCR) using the primers: forward, 5'-ccggaattctggccaccatggaagtgcagaaagaggcac-3', and reverse, 5'-cgcggatcccggaaggccaccacggcccgc-3' , and followed by cloning into EcoRI and BamHI sites of the pEGFP-N1 vector (Clontech, Mountain View, CA, USA) to generate pEGFP-N1-IER2 vector, which contained a Kozak sequence and ATG to be in frame with GFP on the vector. Cells were transfected with pEGFP-N1-IER2 or pEGFP-N1 vector using Lipofectamine 3000 according to the manufacturer's instruction (Invitrogen), and G418-resistant transfectants were selected. Construct expressing shRNA specific targeting ITGB1 (shITGB1) was produced by annealing the synthesized primers, 5'-CCGGCAAGAGAGC TGAAGACTATCTCGAGATAGTCTTCAGCTCTCTTGTTT TTG-3', sense and 5'-AATTCAAAAACAAGAGAGCTGAA GACTATCTCGAGATAGTCTTCAGCTCTCTTG-3', antisense and cloned into the AgeI and EcoRI sites of pGV115, and the non-silencing control shRNA vector (NC) were both obtain from the GeneChem Corporation (Shanghai, China). Cells were transfected with shITGB1 or with NC using Lipofectamine 3000 according to the manufacturer's instruction. ITGB1 promoter was cloned from human genomic DNA by PCR using the primers: forward, 5'-CGGGGTACCGATAGCAGCTTGCCA GTAGC-3' and reverse, 5'-CCCAAGCTTGGTGGCGGCGG CTCCTCCTCCT-3', and then inserted into the pGL3-basic vector (Promega) at KpnI and HindIII sites. All of the constructs were validated by DNA sequencing. The production and transduction of the recombinant lentiviruses encoding IER2 (LV-IER2), shRNA against human IER2 (LV-shR), and indicated control lentiviruses (LV-C and LV-shC) were generated or acquired as previously described (7, 8) . After lentiviral-infection for 48 h, the growth medium was supplemented with puromycin and maintained at least for two weeks to select stably transduced cell lines, and cells were screened for IER2 expression by real-time reverse transcription quantitative PCR (RT-qPCR) and western blotting.
RT-qPCR.
Total RNA was extracted and purified from the cells using the RNA isolator total RNA extraction reagent, and subjected to reverse transcription using the HiScript First Strand cDNA synthesis kit according to the supplier's instruction (Vazyme, Nanjing, China). The real-time PCR and data collection were subsequently performed as described previously using the AceQ ® qPCR SYBR ® Green master mix kit (Vazyme) (12) . Primers used for the amplification were as follows: IER2 forward, 5'-CCAAAGTCAGCCGCAAACGA-3' and reverse, 5'-TTT CTTCCAGACGGGCTTTCTTGC-3'; ITGB1 forward, 5'-AAT GTAACCAACCGTAGC-3' and reverse, 5'-CAGGTCCATAAG GTAGTAGA-3'; integrin α5 (ITGA5) forward, 5'-AGGCAGCT ATGGCGTCCCACTGT-3' and reverse, 5'-CATCAGAGGTG GCTGGAGGCTTG-3'; and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) forward, 5'-GCACCGTCAAGGCTGAG AAC-3' and reverse, 5'-TGGTGAAGACGCCAGTGGA-3' . The relative expression levels of the indicated mRNA normalized against GAPDH mRNA were calculated using the 2 -ΔΔCT methods.
Western blot analysis. Western blot analysis was performed following standard methods. Briefly, cell lysates were prepared, separated and transferred onto polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA). The membranes were then blocked with 5% nonfat dried milk or 3% bovine serum albumin (BSA) for tyrosine phosphorylation blots and incubated with primary antibodies, and followed by incubation with horseradish peroxidase (HRP)-linked secondary antibodies. The antibodies used in the current study were: mouse polyclonal anti-IER2 (1:1,000; Abcam); rabbit monoclonal anti-ITGB1, rabbit polyclonal anti-ITGA5, rabbit monoclonal anti-FAK, rabbit polyclonal anti-pY397FAK, rabbit polyclonal anti-pY576/Y577FAK, rabbit polyclonal anti-pY925FAK, rabbit monoclonal anti-Src, rabbit polyclonal anti-pY527Src Cell migration and invasion assay. Cell migration and invasion assays were performed as described previously (12) . In brief, cells were serum-starved overnight and then 200 µl of 1x10 5 or 2x10 5 cells in serum free medium were seeded in uncoated or Matrigel-coated chambers with 8.0 µm pore sizes (6.5 mm; Costar, Cambridge, MA, USA) of the 24-well Transwell, respectively. The inserts were then placed into the lower chambers containing 600 µl of the complete growth medium. The migrated or invaded cells on the lower surface of the inserts were fixed and stained. Five random fields at x100 magnification were analyzed under a light microscope. Assays were performed in triplicate from three independent experiments.
Cell-ECM adhesion and cell spreading assays. Cell-ECM adhesion assays were performed on the collagen type I, fibronectin and Matrigel (BD Biosciences, Franklin Lakes, NJ, USA), respectively. For collagen type I or fibronectin coated, the 96-well culture plates were coated with 10 µg/ml collagen type I or fibronectin overnight at 4˚C and blocked with 1% BSA in PBS at 37˚C for at least 1 h, and then washed with PBS. For Matrigel coated, Matrigel (200 µg/ml) was added to the 96-well culture plates, incubated at 37˚C for at least 1 h, and blocked with 1% BSA. For cell-ECM adhesion assays, aliquots (100 µl) of cell suspension at a density of 2x10 6 cells/ ml were seeded to each well of the matrix coated 96-well culture plates and allowed to adhere to the matrix for 45 min at 37˚C. Unattached cells were gently removed and adhesive cells were quantified by using the CCK-8 assay according to the supplier's instruction. Assays were performed in six wells from five independent experiments. For cell spreading assays, cells (2x10 5 cells/well) were seeded to each well of the fibronectin coated coverslips in 24-well culture plates prepared as above and incubated at 37˚C for the indicated time. The cells were then fixed immediately with 4% paraformaldehyde and the spreading cells were captured by light microscopy equipped with a digital image capturing system. Spreading cells were defined as cells adherent with protrusions or lamellipodia (fried egg shape), whereas unspreading cells were identified by their round and adherent with less projections appearance. Spreading was quantified from 10 randomly selected fields from three independent experiments.
Chromatin immunoprecipitation (ChIP) assay. The ChIP assay was performed in the cells stably transfected with pEGFP-N1-IER2 or pEGFP-N1 vectors using the SimpleChIP ® Plus Enzymatic Chromatin IP kit (Cell Signaling Technology) according to the supplier's instruction. In brief, cells were grown to confluence in culture dishes and fixed in formaldehyde (1%), scraped from the dishes and lysed, and the homogenized chromatin was sheared by micrococcal nuclease for 20 min at 37˚C and sonicated with several pulses to break the nuclear membrane. The GFP antibody (Invitrogen), positive control histone H3 antibody, or negative control normal rabbit IgG was used to precipitate the precleared cross-linked chromatin at 4˚C overnight with rotation, and followed by adding protein G beads and incubation for 4 h at 4˚C with rotation. After washing, the immunoprecipitated chromatin was eluted from the antibody/protein G beads and purified by reversal of cross-links, removal of RNA with RNase A, and treatment with proteinase K. The immunoprecipitated DNA fragments were performed as the template for PCR using the human ITGB1 promoter-specific primers forward, 5'-TCTTAGACACAGGCAAGCACA-3' and reverse, 5'-CCTGAGTCCCGAGGCAAATC-3' . The PCR products were run on a 2 % agarose gel and visualized with ethidium bromide staining.
Luciferase reporter gene assay. For luciferase reporter gene assay, the luciferase reporter constructs (200 ng) and pTK-Renilla vectors (100 ng) were transiently transfected into the lentiviral-transduced cells in 24-well culture plates using Lipofectamine 3000. After incubation for 48 h, luciferase activities were determined using the luciferase reporter assay system (Promega), and normalized to Renilla luciferase activities.
Statistical analysis. Data are shown as the mean ± stan dard deviation (SD) and analyzed by the Student's t-test. The statistical significance was determined by p<0.05.
Results

IER2 promoted HCC cell migration and invasion.
To understand the contribution of IER2 expression to the biological functions in HCC cells, the lentivirus-mediated IER2 overexpression or knockdown in the low metastatic potential SMMC7721 cells and in the high metastatic potential MHCC97H cells were initially established. Overexpression and knockdown of IER2 in SMMC-7721 cells and in MHCC97H cells were confirmed by RT-qPCR (Figs. 1A and 2A) and western blot analysis (Figs. 1B and C and 2B and C). The data suggested that the indicated lentiviruses have been successfully transduced into the SMMC-7721 and MHCC97H cells, and IER2 overexpression was shown in LV-IER2-infected cells, and efficient knockdown of IER2 was shown in LV-shR-infected cells, thus, the indicated lentiviruses could be used in the following experiments.
We employed lentivirus-mediated IER2 overexpression or knockdown in the SMMC7721 cells and MHCC97H cells, respectively, and performed Transwell cell migration and invasion assays. Compared with the corresponding empty vector-transduced cells (LV-C and LV-shC) and the nontransduced cells [wild-type (WT)], both SMMC-7721 and MHCC97H cells stably transduced with LV-IER2 showed significant increase of the cell migratory and invasiveness capacity, whereas silencing of IER2 obviously attenuated the motility of SMMC-7721 and MHCC97H cells (Fig. 3A-D) . No significant differences in cell motility were observed among the empty vector-infected cells and the WT. In addition, the alteration in cell motility did not appear to be due to affected cell viability and proliferation. Under these conditions, knockdown and the ectopic expression of IER2 had no obvious effects on cell viability and proliferation of SMMC-7721 and MHCC97H cells in vitro (Fig. 3E and F) . These observations supported the notion that IER2 played an important role in HCC cell migra tion and invasion. IER2 regulates cell-ECM adhesion and spreading. Considering that cell adhesion and spreading onto ECM are crucial steps in cellular migration and invasion (13), we then investigated whether IER2 positively regulates HCC cell-ECM adhesion and spreading. Lentiviral-transduced SMMC-7721 or MHCC97H cells were seeded on collagen type I-, Matrigel-or fibronectin-coated 96-well culture plates, respectively, and incubated at 37˚C for 45 min. As shown in Fig. 4 , compared with those in the empty vector-transduced cells and WT, LV-IER2 infection significantly promoted SMMC-7721 or MHCC97H cell adhesion onto the fibronectin, while LV-shR infection decreased the cell adhesion onto the fibronectin (Fig. 4C) . Interestingly, there were no significant alteration in the cell adhesion onto the collagen type I or Matrigel either in IER2 overexpressing cells or IER2 knockdown cells (Fig. 4A and B) . No significant difference was observed either in the LV-C-infected or the LV-shC-infected cells (data not shown). These data demonstrated that IER2 is an important regulator of HCC cell adhesion onto the fibronectin, but not collagen type I or Matrigel, and promotion of the cell motility by IER2 overexpression may be the consequence of the increase cell-fibronectin adhesion, while the reduction in the cell motility induced by IER2 knockdown is likely the consequence of the decreasing cell-fibronectin adhesion.
Since cell spreading is the early phase of cell migration and invasion (13, 14) , and IER2 expression promoted cell adhesion onto the fibronectin (but not collagen type I or Matrigel) as described above, we further examined whether IER2 positively regulated the cell spreading on the fibronectin. With increasing the time of incubation, both SMMC-7721 and MHCC97H cells showed significant increase of the cell spreading (Fig. 5) . Specifically, when compared to empty vector-transduced cells or WT, overexpression of IER2 significantly increased the ability of cells to spread on the fibronectin coated surface (Fig. 5C and D) , and the LV-IER2-transduced cells displayed increased cell spreading surface area and showed lamellopodia around their peripheral edges ( Fig. 5A and B) . On the contrary, IER2 depletion obviously decreased cell spreading on the fibronectin, and these IER2 silencing cells showed poor spreading and exhibited a non-polarized, spherical shape, and few lamellipodi protrusions ( Fig. 5A and B) . No significant difference was found either in the LV-C-transduced or the LV-shC-transduced cells (data not shown). Taken together, these results suggested that IER2 is required for effective spreading and adhesion of HCC cells to fibronectin, and that the increased cell adhesion and spreading of IER2 expressing cells, perhaps account for the promotion of IER2 on migration and invasion.
IER2 promotes ITGB1 expression in HCC cells. ITGA5 and ITGB1 form heterodimers to mediate cell adhesion onto the fibronectin (15) and play very important roles in cell motility (16) (17) (18) . Since IER2 expression positively regulated cell motility, adhesion and spreading onto the fibronectin of the SMMC-7721 and MHCC97H cells (Figs. 3-5) , we then tested whether IER2 expression was correlated with the metastatic potential of HCC cell lines and with ITGA5 or ITGB1 expression both in mRNA and protein levels in HCC cells. Data from RT-qPCR and western blot analysis demonstrated that the HCC cell lines, HepG2, SMMC-7721, MHCC97H and HCCLM3 cells, four HCC cell lines with increasing spontaneous metastatic potential (19) (20) (21) , were shown to express IER2 with relative low expression of IER2 in HepG2 and SMMC-7721 cells, which have low metastatic potential, and abundant expression of IER2 in MHCC97H and HCCLM3 cells, which have high metastatic potential (Fig. 6 ), indicating that IER2 expression was positively correlated with the metastatic potential of HCC cell lines. Moreover, the results showed that IER2 expression was positively correlated with ITGB1 (but not ITGA5) expression in these cell lines with increasing spontaneous metastatic potential (Fig. 6) . We further explored whether IER2 expression may regulate ITGA5 or ITGB1 expression both in mRNA and protein levels. Our results indicated that abundant expression of ITGA5 was found in HCC cell lines (Figs. 6B and 7C and D) , whereas IER2 overexpression or knockdown resulted in significant upregulation or downregulation of ITGB1, but not ITGA5 either in mRNA or protein levels in SMMC-7721 and MHCC97H cells (Fig. 7A-F) , suggesting that IER2 expression levels positively correlate with ITGB1 expression in SMMC-7721 and MHCC97H cells. To verify whether the observed positive correlation of IER2 with the ITGB1 expression is the consequence of the interaction of IER2 with the ITGB1 promoter, the luciferase reporter gene assay and ChIP assay were performed. After transient transfection of the luciferase reporter constructs and the internal control vectors into the indicated lentiviral-transduced SMMC-7721 and MHCC97H cells, overexpression of IER2 markedly upregulated the luciferase activity of the ITGB1 promoter, while knockdown of IER2 significantly decreased the luciferase activity of the ITGB1 promoter in comparison with those in the WT and empty vector-transduced cells ( Fig. 7G and H) . Moreover, results from ChIP assay, which was performed in SMMC-7721 and MHCC97H cells stably transfected with pEGFP-N1-IER2 or pEGFP-N1 vectors, showed that the amplified product of 146 bp was enriched in the pEGFP-N1-IER2 expressing cells relative to that in the negative control IgG and the input (Fig. 7I and J) , indicating that IER2 does interact directly with the ITGB1 promoter. Collectively, these data demonstrated that IER2 may regulate expression of the ITGB1 in HCC cells by direct interaction with the ITGB1 promoter, and indicated that IER2 promoted the cell-fibronectin adhesion and motility of the HCC cells presumably by activating ITGB1 signaling.
Effect of IER2 on the ITGB1-mediated signaling pathway.
In present study we observed that IER2 promoted cell adhesion and spreading on the fibronectin (Figs. 4 and 5 ) and regulated expression of the ITGB1 (Fig. 7) in HCC cell lines, suggesting that IER2-mediated ITGB1 expression may account for the promotion of cell motility by activating ITGB1-mediated signaling pathway. To assess the requirement of ITGB1 in IER2-promoted cell spreading and motility, ITGB1 was knocked down in both SMMC-7721 and MHCC97H cells stably transduced with LV-C or LV-IER2, and these cells were subjected to cell spreading, Transwell migration and invasion assays. As shown in Fig. 8, compared It has been well characterized for most cell types that integrins link ECM to actin filaments activating the integrin-mediated downstream signaling molecules, including FAK, Src and paxillin, thereby regulating the cell-ECM adhesion, spreading and cell motility (16) (17) (18) (22) (23) (24) . We next performed western blot assay to explore whether IER2 expression regulated cell motility by activating FAK-Src-paxillin signaling pathway. As shown in Fig. 9 , compared with those in the WT and empty vector-transduced cells, overexpression of IER2 significantly increased phosphorylation of FAK at Y397 (pY397FAK), Y407 (pY407FAK), Y576/Y577 (pY576/ Y577FAK), Y861 (pY861 FAK), Y925 (pY925FAK) and S910 (pS910FAK), and phosphorylation of Src at Y419 (pY419Src) and paxillin at Y118 (pY118paxillin), and decreased phosphorylation of Src at Y527 (pY527Src). Interestingly, knockdown of IER2 showed a slight, but not significant alteration of phosphorylation of FAK and paxillin, whereas, obvious decrease of pY527Src and increase of pY419Src were shown in IER2 silencing cells, suggesting that IER2 activated ITGB1-mediated signal pathway is likely a part of a mechanism that participates in modulation of cell motility and adhesion of HCC cells. No significant differences were found either in the LV-C-transduced or the LV-shC-transduced cells (data not shown). Taken together, these results indicated that IER2-mediated ITGB1 expression is partially responsible for IER2-promoted cell-fibronectin adhesion and motility of the HCC cells, providing a novel molecular mechanism for IER2 promoting cell adhesion and motility.
Discussion
Previously, a study showed that IER2 plays a role in tumor cell motility and metastasis (6), and we also found that IER2 promotes the motility of SMMC-7721 and HepG2 cells (8) . However, the detailed roles and underlying molecular mechanisms in HCC remained unknown. In this study, we investigated the effects of IER2 on the migration, invasion, cell-ECM adhesion and spreading of two HCC cell lines SMMC-7721 with low metastatic potential and MHCC97H with high metastatic potential, and identified IER2 as a regulator of cell-fibronectin adhesion, spreading and motility of these two cell lines. We further defined a new pathway that involves the cell-ECM adhesion molecule ITGB1, and demonstrated the novel IER2-ITGB1 signaling critically contributed to the HCC cell-ECM adhesion and motility. In this study, we first found that IER2 overexpression obviously induced cell migration and invasion, while silencing of IER2 decreased the motility of both SMMC-7721 and MHCC97H cells, suggesting that IER2 may function as an important regulator in HCC cell migra tion and invasion. Since cell motility requires cell-ECM adhesion, spreading and then invading the ECM (13-15,25) we next evaluated whether IER2 induced HCC cell migration and invasion via its regulation for the cell-ECM adhesion and spreading. We demonstrated that IER2 overexpression promoted SMMC-7721 or MHCC97H cell adhesion and spreading onto the fibronectin (but not collagen type I or Matrigel), whereas IER2 knockdown repressed cell adhesion and spreading onto the fibronectin. Taken together, these findings indicated that IER2 is an important regulator of cell spreading and adhesion onto the fibronectin, and promotion of the cell motility by IER2 overexpression may be due to the increase in cell-fibronectin adhesion and spreading, whereas the decrease in the cell motility caused by IER2 depression is probably attributed to the decreasing cell-fibronectin adhesion and spreading, and the endogenous IER2 expression is required for cell motility and adhesion.
Integrins are the major ECM receptors that consist of α and β subunits and play very important roles in cell motility and tumor progression, especially in tumor invasion and metastasis (16) (17) (18) 26) . Among integrins, the heterodimers of ITGA5 and ITGB1, receptors for fibronectin, are thought to mediate tumor cell adhesion to fibronectin and closely correlate with cancer progression and metastasis (18) . In the present study, we demonstrated that IER2 expression was positively correlated with the metastatic potential and associated with ITGB1 expression levels in HCC cell lines. These results prompted us to examine whether IER2 may regulate the expression of ITGA5 and ITGB1. We showed that IER2 expression enhanced ITGB1 expression both in mRNA and protein levels in SMMC-7721 and MHCC97H cells, while knockdown of IER2 reduced ITGB1 expression. Abundant expression of ITGA5 was observed in HCC cell lines, but neither IER2 overexpression nor knockdown altered the expression of ITGA5 either in mRNA or protein levels in SMMC-7721 and MHCC97H cells. We also demonstrated that IER2 may regulate expression of ITGB1 in HCC cell lines by functioning as a potential transcriptional factor or transcriptional co-activator for ITGB1. Furthermore, we silenced ITGB1 in both SMMC-7721 and MHCC97H cells stably transduced with LV-C or LV-IER2, and found that the increase of cell migration, invasion, and spreading on fibronectin in IER2 overexpressing cells was prevented by knockdown of ITGB1. Collectively, these findings suggested that IER2-induced cell-fibronectin adhesion, spreading and motility of the HCC cells may be mediated, at least in part, by promotion of ITGB1.
It is well documented that ITGB1 is the classic fibronectin receptor and mediates cell adhesion onto the ECM and confers higher metastatic capacity to a number of cancer cells (27) (28) (29) . Upon integrin-mediated signaling activation, the heterodimers of ITGA5 and ITGB1 link fibronectin to induce phosphorylation of the FAK at Y397 and formation of the active FAK/Src complex, followed by further phosphorylation at other sites on the FAK and other downstream signaling molecules including paxillin, and subsequently modulating cell motility and cell-fibronectin adhesion (24, 30, 31) . Therefore, we further examined the role of IER2 in the integrin-mediated signaling pathway. We found that the FAK phosphorylation (at Y397, Y407, Y576/Y577, Y861, Y925 and S910), Src phosphorylation (at Y419), and paxillin phosphorylation were significantly upregulated, and the Src phosphorylation at Y527 [the inhibitory site for Src activation (32) ] was downregulated in IER2 overexpressing HCC cells, suggesting that IER2 overexpression promoted HCC cell-fibronectin adhesion, spreading and motility by activating FAK, Src and paxillin via ITGB1. Unexpectedly, we did not find obvious opposite effects in IER2 knockdown cells. We found that silencing of IER2 resulted in only a slight, but no significant alteration of phosphorylation of FAK and paxillin, but also significant decrease of pY527Src and increase of pY419Src, suggesting that IER2 may have some uncharacterized functions or potential partners to regulate HCC cell motility and adhesion, and that IER2 activated ITGB1-mediated signal pathway is likely a part of a mechanism that participates in modulation of cell motility and adhesion of HCC cells. Collectively, these findings indicated that IER2-mediated ITGB1 expression and activation of ITGB1-FAK-Src-paxillin signal pathway was likely, at least in part, responsible for IER2-promoted cell-ECM adhesion and motility of the HCC cells, and studies to identify potential partners and the detail mechanisms of IER2 in regulating HCC cell-ECM adhesion and motility are under way.
In conclusion, we demonstrated a novel pathway modulating HCC cell motility and cell-ECM adhesion by IER2, and identified that IER2 expression is positively correlated with the metastatic potential of HCC cell lines, and that IER2 promoted HCC cell motility and the cell-fibronectin adhesion as the result of the activation of the ITGB1-FAK-Src-paxillin signal pathway. Further study of the underlying mechanism as to how IER2 depletion coordinates the ITGB1-FAK-Src-paxillin signaling is ongoing, however, the findings presented here may reinforce a role for IER2 as a novel molecular target for HCC.
